Jin Medical International Ltd.
ZJYL Nasdaq· Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last close · Oct 26, 2026
$1.94
KIRA · Stoqly’s AI analyst, in plain words
- Jin Medical International Ltd. had $20.7M of revenue in fiscal 2025, down 12.0% on the year before.
- Its operating margin was 2.9%, down 12.5 pts: of every 100 in sales, about 3 is left after running the business.
- Jin Medical International Ltd. made $1.2M of net profit in fiscal 2025. From fiscal 2021 to 2025, diluted EPS grew −15.9% a year.
- Free cash flow was −$3.7M in fiscal 2025, −18.0% of revenue.
- Jin Medical International Ltd. has $10.8M more cash than debt.
Market cap
$304M
P/E
194.0x
Revenue
$20.7M
Net income
$1.2M
Free cash flow
−$3.7M
Operating margin
2.9%
Jin Medical International Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−12.0%
No. Sales fell 12.0% last year.
Does it make a profit?
5.8%
A little. It keeps 5.8% of every sale as profit.
Does profit turn into cash?
−18.0%
No. It spent more cash than it brought in.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
194.0x
One share costs 194.0 times its yearly profit per share.
What Jin Medical International Ltd. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 20-F · Feb 10, 2026
- Legal name
- Jin Medical International Ltd.
- CIK
- 0001837821
Jin Medical International Ltd. · ZJYL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $20.8M | $19.2M | $19.8M | $23.5M | $20.7M |
| Revenue growth | — | −7.6% | 3.3% | 18.6% | −12.0% |
| Net interest income | −$0.0M | $0.2M | $0.2M | — | — |
| Gross margin | 30.6% | 32.3% | 34.2% | 40.4% | 29.2% |
| Operating margin | 12.7% | 11.1% | 14.5% | 15.5% | 2.9% |
| Net income | $2.6M | $2.7M | $2.9M | $3.7M | $1.2M |
| Net margin | 12.7% | 14.1% | 14.5% | 15.6% | 5.8% |
| Diluted EPS | $0.02 | $0.02 | $0.02 | $0.02 | $0.01 |
| Cash | |||||
| Cash from operations | $5.8M | $1.6M | $3.1M | −$1.2M | $2.9M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.1M | $6.6M |
| Free cash flow | $5.8M | $1.5M | $3.0M | −$1.4M | −$3.7M |
| FCF margin | 27.9% | 8.0% | 15.1% | −5.8% | −18.0% |
| Share count change | — | 0.0% | 7.5% | 7.8% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $3.7M | $7.1M | $16.7M | $26.8M | $29.6M |
| Debt incl. finance leases | — | — | $4.1M | $11.3M | $18.8M |
| Shareholders' equity | $14.0M | $15.2M | $24.0M | $28.8M | $29.6M |
| Net debt / EBITDA | — | — | −4.1x | −4.0x | −12.7x |
| Current ratio | — | 3.3x | 3.5x | 2.5x | 1.9x |
| Returns and quality | |||||
| Return on capital | — | — | 22.5% | 22.2% | 2.8% |
| Return on equity | 18.8% | 18.5% | 14.7% | 13.9% | 4.1% |
| Return on tangible equity | 18.8% | 17.8% | 12.1% | 13.3% | 4.2% |
| Piotroski F-score | — | — | 5 | 2 | 3 |
| Altman Z'' | — | 9.9 | 9.5 | 7.4 | 5.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jin Medical International Ltd. · ZJYL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.94 a share, the company is worth $304M: 194.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001837821). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.